1. Home
  2. JELD vs CGTX Comparison

JELD vs CGTX Comparison

Compare JELD & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

HOLD

Current Price

$1.63

Market Cap

110.5M

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.25

Market Cap

114.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JELD
CGTX
Founded
1960
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
110.5M
114.4M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
JELD
CGTX
Price
$1.63
$1.25
Analyst Decision
Hold
Strong Buy
Analyst Count
6
3
Target Price
$3.43
$3.33
AVG Volume (30 Days)
2.2M
997.7K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
$3,211,181,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.93
$0.22
52 Week High
$6.98
$3.83

Technical Indicators

Market Signals
Indicator
JELD
CGTX
Relative Strength Index (RSI) 61.62 58.69
Support Level $0.93 $1.01
Resistance Level $2.06 $1.36
Average True Range (ATR) 0.14 0.09
MACD 0.04 0.01
Stochastic Oscillator 90.72 62.50

Price Performance

Historical Comparison
JELD
CGTX

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: